Results 171 to 180 of about 15,753,813 (238)

Single‐Cell RNA Sequencing of Peripheral Blood Defines Two Immunologic Subtypes of Sjögren's Disease Distinguished by Anti‐SSA Antibodies and Aberrant B Cell Populations

Arthritis &Rheumatology, EarlyView.
Objective Sjögren's disease (SjD) is a heterogeneous autoimmune disorder characterized by substantial clinical and molecular diversity. This heterogeneity raises key questions regarding the existence of distinct pathogenic mechanisms underlying disease subtypes.
Geoffrey Urbanski, Kimberly E. Taylor, Emily Flynn, Armita Norouzi, Catherine Chu, Brittany Davidson, Arnab Ghosh, Joanne Nititham, Ravi K. Patel, Annie W. Poon, Gabriela K. Fragiadakis, Alexis J. Combes, Walter L. Eckalbar, Lindsey A. Criswell, Chun Jimmie Ye, Caroline H. Shiboski   +15 more
wiley   +1 more source

Deficiency in T follicular regulatory cells promotes autoimmunity. [PDF]

J Exp Med, 2018
Fu W, Liu X, Lin X, Feng H, Sun L, Li S, Chen H, Tang H, Lu L, Jin W, Dong C.   +10 more
europepmc   +1 more source

Treatment‐Driven Peripheral Blood Transcriptomic Remodeling and Baseline Predictors of ESSDAI and STAR Response to B Cell Therapy in Sjögren's Disease

Arthritis &Rheumatology, EarlyView.
Graphical Abstract Objective This study aimed to characterize whole blood transcriptomic profiles in adults with active Sjögren's disease (SjD) treated with anti‐CD20 or B lymphocyte stimulator/BAFF inhibition, identify markers of clinical response, and define inflammatory pathways linked to nonresponse. Methods Whole blood RNA sequencing was performed
Aimen Ibrahim, Junjie Peng, Eileen Tian, Lucia Martin‐Gutierrez, John Casement, Kyle Thompson, Wan‐Fai Ng, André van Maurik, Elizabeth C. Jury, Coziana Ciurtin   +9 more
wiley   +1 more source

Roles of T Follicular Helper Cells and T Follicular Regulatory Cells in Autoantibody Production in IL-2-Deficient Mice. [PDF]

Immunohorizons, 2019
Xie MM, Liu H, Corn C, Koh BH, Kaplan MH, Turner MJ, Dent AL.   +6 more
europepmc   +1 more source

Spatial distribution and function of T follicular regulatory cells in human lymph nodes. [PDF]

J Exp Med, 2018
Sayin I, Radtke AJ, Vella LA, Jin W, Wherry EJ, Buggert M, Betts MR, Herati RS, Germain RN, Canaday DH.   +9 more
europepmc   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

A distinct subpopulation of CD25^- T-follicular regulatory cells localizes in the germinal centers. [PDF]

Proc Natl Acad Sci U S A, 2017
Wing JB, Kitagawa Y, Locci M, Hume H, Tay C, Morita T, Kidani Y, Matsuda K, Inoue T, Kurosaki T, Crotty S, Coban C, Ohkura N, Sakaguchi S.   +13 more
europepmc   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

T follicular regulatory cells in the regulation of B cell responses. [PDF]

Trends Immunol, 2015
Sage PT, Sharpe AH.
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source